Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Frontage to Acquire Quintara Discovery | Contract Pharma

What are you searching for?

Sign in
Breaking News

Frontage to Acquire Quintara Discovery

Quintara provides in vitro ADME profiling, bioanalytical services, and dedicated assay development and compound screening.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Global contract research organization (CRO) Frontage Laboratories has entered into a deal to acquire Quintara Discovery, a drug discovery and development specialist based in the San Francisco Bay Area.
 
Established in 2013, Quintara provides in vitro ADME profiling, bioanalytical services, and dedicated assay development and compound screening.
 
“Quintara has an exceptional discovery and development platform that it has leveraged to build a strong reputation with its clients,” said According Song Li, founder, chairman and CEO of Frontage. “Following the addition of the Quintara team’s significant expertise in the areas of discovery and ADME profiling, Frontage will speed up its expansion in drug discovery services. We also expect that Quintara’s location in the San Francisco Bay Area will facilitate the growth of our business on the west coast.”
 
Wentao Zhang, founder and president, Quintara, said, “Frontage has clearly emerged as an extremely strong and highly-regarded CRO partner in the drug development process and we are very enthusiastic about the new opportunities that this transaction will bring to both the Quintara team and our clients. Quintara’s proven discovery platform will complement the wide variety of high-caliber pre-clinical services offered by Frontage Labs, enabling us to provide more integrated pre-clinical services to our clients.”
 
The transaction is expected to close in the third quarter of 2021.
 
Frontage Laboratories provides product development services from drug discovery to late phase clinical process. Services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics